Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic

Pemphigus is a rare autoimmune disease characterised by the production of pathogenic autoantibodies in response to different desmosome proteins. The pathophysiological process leads to the development of blisters and erosions on mucosal and/or skin surfaces. The classical clinical variants of pemphi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Branka Marinović, Joško Miše, Ines Lakoš Jukić, Zrinka Bukvić Mokos
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/405b8992aae6401696d41ee5350fae14
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:405b8992aae6401696d41ee5350fae14
record_format dspace
spelling oai:doaj.org-article:405b8992aae6401696d41ee5350fae142021-11-25T16:48:59ZPemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic10.3390/biomedicines91115552227-9059https://doaj.org/article/405b8992aae6401696d41ee5350fae142021-10-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1555https://doaj.org/toc/2227-9059Pemphigus is a rare autoimmune disease characterised by the production of pathogenic autoantibodies in response to different desmosome proteins. The pathophysiological process leads to the development of blisters and erosions on mucosal and/or skin surfaces. The classical clinical variants of pemphigus are pemphigus vulgaris and pemphigus foliaceus. A diagnostic delay is very common in pemphigus, especially among patients with mucosal involvement. However, in recent years we have witnessed considerably fewer patients with extensive mucocutaneous manifestations, since patients with oral lesions are referred to dermatologists to start the treatment much sooner than they had been previously. Among non-classical variants of pemphigus, unusual cases with discrepancies between autoantibody profiles and clinics challenge the “desmoglein compensation theory”. The identification of several other autoantigens that perform a role in the pathogenesis of different variants of pemphigus will progress immunodermatology towards an approach that will determine personalized pemphigus subtypes for each patient. Comorbidities among patients are primarily associated with the prolonged use of corticosteroids and other immunosuppressive agents. The SARS-CoV-2 pandemic raised concerns regarding the immunosuppressive effects of treatment and the risk of a more complicated COVID-19 infection, as well as on the ability to develop an adequate vaccine response.Branka MarinovićJoško MišeInes Lakoš JukićZrinka Bukvić MokosMDPI AGarticlepemphigusdesmogleinrituximabimmunodermatologyCOVID-19SARS-CoV-2Biology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1555, p 1555 (2021)
institution DOAJ
collection DOAJ
language EN
topic pemphigus
desmoglein
rituximab
immunodermatology
COVID-19
SARS-CoV-2
Biology (General)
QH301-705.5
spellingShingle pemphigus
desmoglein
rituximab
immunodermatology
COVID-19
SARS-CoV-2
Biology (General)
QH301-705.5
Branka Marinović
Joško Miše
Ines Lakoš Jukić
Zrinka Bukvić Mokos
Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic
description Pemphigus is a rare autoimmune disease characterised by the production of pathogenic autoantibodies in response to different desmosome proteins. The pathophysiological process leads to the development of blisters and erosions on mucosal and/or skin surfaces. The classical clinical variants of pemphigus are pemphigus vulgaris and pemphigus foliaceus. A diagnostic delay is very common in pemphigus, especially among patients with mucosal involvement. However, in recent years we have witnessed considerably fewer patients with extensive mucocutaneous manifestations, since patients with oral lesions are referred to dermatologists to start the treatment much sooner than they had been previously. Among non-classical variants of pemphigus, unusual cases with discrepancies between autoantibody profiles and clinics challenge the “desmoglein compensation theory”. The identification of several other autoantigens that perform a role in the pathogenesis of different variants of pemphigus will progress immunodermatology towards an approach that will determine personalized pemphigus subtypes for each patient. Comorbidities among patients are primarily associated with the prolonged use of corticosteroids and other immunosuppressive agents. The SARS-CoV-2 pandemic raised concerns regarding the immunosuppressive effects of treatment and the risk of a more complicated COVID-19 infection, as well as on the ability to develop an adequate vaccine response.
format article
author Branka Marinović
Joško Miše
Ines Lakoš Jukić
Zrinka Bukvić Mokos
author_facet Branka Marinović
Joško Miše
Ines Lakoš Jukić
Zrinka Bukvić Mokos
author_sort Branka Marinović
title Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic
title_short Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic
title_full Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic
title_fullStr Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic
title_full_unstemmed Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic
title_sort pemphigus—the crux of clinics, research, and treatment during the covid-19 pandemic
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/405b8992aae6401696d41ee5350fae14
work_keys_str_mv AT brankamarinovic pemphigusthecruxofclinicsresearchandtreatmentduringthecovid19pandemic
AT joskomise pemphigusthecruxofclinicsresearchandtreatmentduringthecovid19pandemic
AT ineslakosjukic pemphigusthecruxofclinicsresearchandtreatmentduringthecovid19pandemic
AT zrinkabukvicmokos pemphigusthecruxofclinicsresearchandtreatmentduringthecovid19pandemic
_version_ 1718412949352087552